Japan manages confidential information from drug quality audits by adhering to strict regulatory frameworks, such as the Pharmaceuticals and Medical Devices Agency (PMDA) guidelines. These include secure data handling, limited access to sensitive information, and confidentiality agreements with stakeholders, ensuring compliance with international standards and protecting proprietary data from unauthorized disclosure.
